MIST
Income statement / Annual
Last year (2023), Milestone Pharmaceuticals Inc.'s total revenue was $1.00 M,
a decrease of 80.00% from the previous year.
In 2023, Milestone Pharmaceuticals Inc.'s net income was -$59.69 M.
See Milestone Pharmaceuticals Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$1.00 M
|
$5.00 M
|
$15.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$598,000.00 |
$480,000.00 |
$0.00 |
$376,000.00 |
$236,000.00 |
$10,000.00 |
$8,000.00 |
| Gross Profit |
$402,000.00 |
$4.52 M |
$15.00 M |
-$376,000.00 |
-$236,000.00 |
-$10,000.00 |
-$8,000.00 |
| Gross Profit Ratio |
0.4 |
0.9 |
1 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$31.05 M
|
$39.83 M
|
$38.67 M
|
$34.49 M
|
$41.99 M
|
$16.85 M
|
$5.64 M
|
| General & Administrative
Expenses |
$15.93 M
|
$15.72 M
|
$12.40 M
|
$10.29 M
|
$7.00 M
|
$3.05 M
|
$1.50 M
|
| Selling & Marketing
Expenses |
$15.11 M
|
$9.10 M
|
$7.00 M
|
$5.94 M
|
$8.89 M
|
$3.92 M
|
$1.13 M
|
| Selling, General &
Administrative Expenses |
$31.05 M
|
$24.81 M
|
$19.40 M
|
$16.22 M
|
$15.90 M
|
$6.97 M
|
$2.63 M
|
| Other Expenses |
$0.00 |
$0.00 |
$7.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$62.10 M |
$64.64 M |
$58.07 M |
$50.71 M |
$57.88 M |
$23.82 M |
$8.27 M |
| Cost And Expenses |
$62.10 M |
$64.64 M |
$58.07 M |
$50.71 M |
$57.88 M |
$23.82 M |
$8.27 M |
| Interest Income |
$3.97 M |
$1.25 M |
$220,000.00 |
$726,000.00 |
$2.60 M |
$711,000.00 |
$186,000.00 |
| Interest Expense |
$2.55 M |
$0.00 |
$0.00 |
$726,000.00 |
$2.60 M |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$92,000.00
|
$480,000.00
|
$362,000.00
|
$376,000.00
|
$236,000.00
|
$10,000.00
|
$8,000.00
|
| EBITDA |
-$56.85 M
|
-$58.36 M
|
-$42.98 M
|
-$50.71 M
|
-$57.88 M
|
-$23.36 M
|
-$8.26 M
|
| EBITDA Ratio |
-56.85 |
-11.93 |
-2.87 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-61.1
|
-11.93
|
-2.87
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$1.41 M
|
$1.25 M
|
$220,000.00
|
$726,000.00
|
$2.60 M
|
$711,000.00
|
$186,000.00
|
| Income Before Tax |
-$59.69 M |
-$58.39 M |
-$42.85 M |
-$49.98 M |
-$55.29 M |
-$23.11 M |
-$8.08 M |
| Income Before Tax Ratio
|
-59.69
|
-11.68
|
-2.86
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$1.25 M |
-$220,000.00 |
-$17,000.00 |
-$56,000.00 |
$74,000.00 |
$4,000.00 |
| Net Income |
-$59.69 M |
-$57.13 M |
-$42.63 M |
-$49.97 M |
-$55.23 M |
-$23.19 M |
-$8.09 M |
| Net Income Ratio |
-59.69 |
-11.43 |
-2.84 |
0 |
0 |
0 |
0 |
| EPS |
-1.39 |
-1.35 |
-1.02 |
-1.7 |
-3.5 |
-0.98 |
-0.34 |
| EPS Diluted |
-1.39 |
-1.35 |
-1.02 |
-1.7 |
-3.5 |
-0.98 |
-0.34 |
| Weighted Average Shares
Out |
$42.96 M
|
$42.45 M
|
$41.83 M
|
$29.34 M
|
$15.78 M
|
$23.65 M
|
$23.65 M
|
| Weighted Average Shares
Out Diluted |
$42.96 M
|
$42.45 M
|
$41.83 M
|
$29.34 M
|
$15.78 M
|
$23.65 M
|
$23.65 M
|
| Link |
|
|
|
|
|
|
|
